The aim of this article is to present a case of a phenobarbital-induced gingival hyperplasia (GH), discuss possible etiological mechanisms of drug-induced GH, and to present a concise review of the literature.
Introduction
Gingival hyperplasia (GH) has an unpleasant appearance and renders a patient susceptibile to periodontal disease due to the inhabitation of gingival sulcus with periopathogenic bacteria. 1 GH can be the result of a serious adverse drug reaction with potential clinical implications. Histologically, this lesion consists of dense collagenous fibers, acanthosis of the epithelial lining, elongated rete ridges, and sparse fibroblasts. Three main classes of drugs known to cause GH are anticonvulsants, antihypertensive calcium antagonists, and the immunosuppressant, cyclosporine. Phenytoin, primidone, and, very rarely, sodium valproate are among the potential inducers of GH. Phenobarbital-induced GH is an exceedingly rare condition; to our knowledge only one report exists in the literature to date.
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Case Report
Diagnosis
A 28-year-old male patient with epilepsy who had been treated successfully with phenobarbital (120 mg/day) for the past three years presented to the Department of Periodontics at the Tabriz University of Medical Sciences in Tabriz, Iran with a chief complaint of "enlarging gums." The initial physical examination revealed a generalized and firm overgrowth of the gingiva throughout the maxillary and mandibular alveolar ridges. The overgrowth was more prominent on the buccal aspect of the maxillary arch with mild gingival inflammation present throughout the enlarged tissue ( Figure 1 ).
General physical examination was otherwise unremarkable and hematological investigations were normal.
Gram staining of the gingival biopsy specimens showed several gram-positive cocci and bacilli. However, the culture was negative for any bacterial growth. Histological examination of the gingival biopsy revealed a hyperplastic epithelium (pseudoepitheliomatous hyperplasia), epithelial acanthosis, and elongated rete ridges. Obviously, enhanced dense collagenous fibers and a proliferation of fibroblasts were also present ( Figure 2 ).
Given the history and histological findings, the gingival lesion was diagnosed as phenobarbitalinduced gingival hyperplasia. 
Treatment
The patient underwent surgical excision of the hyperplastic gingiva and was trained in the use of vigorous oral hygiene measures. Despite the continued use of a low-dose phenobarbital regimen (100 mg/day), no recurrence of the gingival lesion was observed at a six-year follow-up examination.
Discussion
The present case is believed to be one of the two reports of phenobarbital-induced gingival hyperplasia. Sinha et al. 2 reported a case involving a young man who had developed progressive GH following an 11-year administration of phenobarbital (60-100 mg/ day). 2 However, the patient had intermittently used several other drugs during that time period making the condition more complex.
GH has several adverse consequences. Cosmetic problems related to GH are a potential concern both for the patient and the clinician. The gross enlargement of gingiva may lead to the formation of new habitats due to the development of pocket/pseudopocket configurations of the tissue. This results in the formation of new habitats with a different gas phase (oxygen saturation), 1 fluid phase (gingival crevicular fluid characteristics), 3 and solid phase (gingival tissue) characteristics, considered a favorable environment for certain periopathogenic bacteria. 1 An increase in the accumulation of bacterial plaque, infection, and bleeding are other probable consequences of GH.
Several mechanisms have been proposed for anticonvulsant-induced GH. The presence of phenytoin-sensitive or phenytoin-stable subpopulations of gingival fibroblasts may play a role in this phenomenon. 4, 5 Given the effect of phenytoin on the immune system, immunological reactions mediated by T-cells may be involved in the pathogenesis of anticonvulsant-induced GH. 5 Also, drug-induced immunosuppression may be a contributing factor in the development of GH. 6 Finally, the decrease in sodium flux and cellular folic acid uptake leading to a localized folate deficiency have been suggested as the underlying mechanisms. 5, 7 Dental plaque has also been heavily incriminated as a causative cofactor. 5 The pseudoepitheliomatous hyperplasia (PEH) of the present lesion was an interesting finding. The epidermal growth factor (EGF) and transforming growth factor-α (TGF-α) are both the ligands of the EGF receptor (EGFR). 8 Phenobarbital inhibits EGF binding to its receptor. 9 This would lead to the increased binding of TGF-α which has a lower affinity than EGF to the EGFR. Furthermore, it has been shown the TGF-α is associated with the development of PEH. 10 Taken together, we hypothesized phenobarbital induced the PEH through alteration of EGF/TGF-α ratio.
Summary
Phenobarbital-induced gingival hyperplasia is a quite rare clinical entity which necessitates meticulous evaluation. However, it seems to show a benign behavior with reference to recurrence after surgical excision.
